Hear­ing loss spe­cial­ists at Fre­quen­cy pin the blame for PhI­Ia flop on tri­al de­sign — but they could­n't stem a freefall in share price

When Fre­quen­cy Ther­a­peu­tics scored $80 mil­lion in cash from Astel­las to jump­start an al­liance, the biotech cau­tious­ly point­ed to Phase I/II da­ta bol­ster­ing hope …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER